Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (pts)

1. Molina, M. A.
2. Camps, C.
3. Penas, R. De las
4. Alonso, G.
5. Lopez-Vivanco, G.
6. Provencio, M.
7. Gonzalez-Larriba, J. L.
8. Salazar, F.
9. Sanchez, J. J.
10. Rosell, R.